It is crucial for childhood cancer survivors (CCSs) to manage metabolic syndrome. The prevalence and predictive factors of metabolic syndrome components in CCSs were investigated.
Methods:
This study included CCSs who were diagnosed with cancer under the age of 20 and completed therapy more than 1 year ago. The anthropometric and laboratory data were obtained from the medical records retrospectively. The reference group was extracted from the Korea National Health and Nutrition Examination Survey (2016–2019).
Results:
Of the participants, 29.1% (75 of 258) of the CCSs and 26.4% (1339 of 5081) of the reference group were obese. Blood pressure and triglyceride levels were significantly different in the two groups. Metabolic syndrome was identified in 35 of 258 (13.6%) patients. The reference group showed a 9.4% of prevalence (480 of 5086) (p = 0.028). A total of 127 of 230 (59.6%) met at least one of the dyslipidemia criteria. In multivariate analysis, current age and growth hormone deficiency (GHD) (OR = 5.905) were significant prognostic factors for dyslipidemia, and GHD was a significant prognostic factor for hypertriglyceridemia (OR = 2.864, p = 0.0316) and hypercholesterolemia (OR = 3.053, p = 0.0467). Cranial radiotherapy (RT) was a prognostic variable for hyper low-density lipoprotein cholesterolemia (OR = 2.866, p = 0.0032).
Conclusions:
The frequency of metabolic syndrome was higher in CCSs compared with the reference group. Dyslipidemia was common in CCSs with clinical parameters such as GHD and cranial RT. Risk-based long-term follow-up is needed, and early intervention is required for CCSs.
Get full access to this article
View all access options for this article.
References
1.
ParkHJ, MoonEK, YoonJY, et al.Incidence and Survival of Childhood Cancer in Korea. Cancer Res Treat. 2016; 48(3):869–82.
2.
SuhE, StrattonKL, LeisenringWM, et al.Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020; 21(3):421–35.
3.
MulrooneyDA, YeazelMW, KawashimaT, et al.Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009; 339:b4606.
4.
SaklayenMG.The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12.
5.
ChuehHW, YooJH. Metabolic syndrome induced by anticancer treatment in childhood cancer survivors. Ann Pediatr Endocrinol Metab. 2017; 22(2):82–9.
6.
TalvensaariKK, LanningM, TapanainenP, KnipM. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1996; 81(8):3051–5.
7.
PluimakersVG, van WaasM, NeggersS, van den Heuvel-EibrinkMM. Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors. Crit Rev Oncol Hematol. 2019; 133:129–41.
8.
KimM, KimIH, LimMK, et al.Increased prevalence of metabolic syndrome in adult cancer survivors: asian first report in community setting. Cancer Epidemiol. 2019; 58:130–6.
9.
LeeJY, ParkNH, SongYS, et al.Prevalence of the metabolic syndrome and associated factors in korean cancer survivors. Asian Pac J Cancer Prev. 2013; 14(3):1773–80.
10.
ShinH, ChoiYJ, LeeYH, et al.Prevalence of the components of metabolic syndrome in childhood cancer survivors. Clin Pediatr Hematol Oncol. 2014; 21(1):23–8.
11.
SohnYB, KimSJ, ParkSW, et al.The metabolic syndrome and body composition in childhood cancer survivors. Korean J Pediatr. 2011; 54(6):253–9.
12.
SaultierP, AuquierP, BertrandY, et al.Metabolic syndrome in long-term survivors of childhood acute leukemia treated without hematopoietic stem cell transplantation: an L.E.A. study. Haematologica. 2016; 101(12):1603–10.
13.
OudinC, SimeoniMC, SirventN, et al.Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood. 2011; 117(17):4442–8.
14.
OudinC, AuquierP, BertrandY, et al.Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study. Bone Marrow Transplant. 2015; 50(11):1438–44.
15.
NottageKA, NessKK, LiC, et al.Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol. 2014; 165(3):364–74.
16.
ChowEJ, SimmonsJH, RothCL, et al.Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant. 2010; 16(12):1674–81.
17.
van WaasM, NeggersSJ, PietersR, van den Heuvel-EibrinkMM. Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. Ann Oncol. 2010; 21(5):1121–6.
18.
van WaasM, NeggersSJ, RaatH, et al.Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors. PLoS One. 2012; 7(12):e52237.
19.
de HaasEC, OostingSF, LefrandtJD, et al.The metabolic syndrome in cancer survivors. Lancet Oncol. 2010; 11(2):193–203.
20.
JamesWP, ChunmingC, InoueS. Appropriate Asian body mass indices?. Obes Rev. 2002; 3(3):139.
21.
ZhangFF, KellyMJ, SaltzmanE, et al.Obesity in pediatric ALL survivors: a meta-analysis. Pediatrics. 2014; 133(3):e704–15.
22.
Mostoufi-MoabS, SeidelK, LeisenringWM, et al.Endocrine Abnormalities in Aging Survivors of Childhood Cancer: a Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2016; 34(27):3240–7.
23.
KhanSS, NingH, WilkinsJT, et al.Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol. 2018; 3(4):280–7.
24.
WilsonCL, LiuW, YangJJ, et al.Genetic and clinical factors associated with obesity among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort. Cancer. 2015; 121(13):2262–70.
25.
NevilleKA, CohnRJ, SteinbeckKS, et al.Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab. 2006; 91(11):4401–7.
26.
NathanPC, JovcevskaV, NessKK, et al.The prevalence of overweight and obesity in pediatric survivors of cancer. J Pediatr. 2006; 149(4):518–25.
27.
GurneyJG, NessKK, StovallM, et al.Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab. 2003; 88(10):4731–9.
28.
MeachamLR, GurneyJG, MertensAC, et al.Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study. Cancer. 2005; 103(8):1730–9.
29.
GuollaL, MorrisonKM, BarrRD. Adiposity in Survivors of Cancer in Childhood: how is it Measured and Why Does it Matter?. J Pediatr Hematol Oncol. 2021; 43(1):1–11.
30.
HeymsfieldSB, WaddenTA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3):254–66.
31.
Siviero-MiachonAA, Spinola-CastroAM, Guerra-JuniorG. Adiposity in childhood cancer survivors: insights into obesity physiopathology. Arq Bras Endocrinol Metabol. 2009; 53(2):190–200.
32.
van WaasM, NeggersSJ, UitterlindenAG, et al.Treatment factors rather than genetic variation determine metabolic syndrome in childhood cancer survivors. Eur J Cancer. 2013; 49(3):668–75.
33.
JaniszewskiPM, OeffingerKC, ChurchTS, et al.Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2007; 92(10):3816–21.
34.
LustigRH, PostSR, SrivannaboonK, et al.Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab. 2003; 88(2):611–6.
35.
ShalitinS, LaurE, LebenthalY, et al.Endocrine complications and components of the metabolic syndrome in survivors of childhood malignant non-brain solid tumors. Horm Res Paediatr. 2014; 81(1):32–42.
36.
MillerTL, LipsitzSR, Lopez-MitnikG, et al.Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev. 2010; 19(8):2013–22.
37.
CookseyR, WuSY, KlesseL, et al.Metabolic syndrome is a sequela of radiation exposure in hypothalamic obesity among survivors of childhood brain tumors. J Invest Med. 2019; 67(2):295–302.
38.
ConstineLS, WoolfPD, CannD, et al.Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med. 1993; 328(2):87–94.
39.
GuranT, TuranS, BereketA, et al.The role of leptin, soluble leptin receptor, resistin, and insulin secretory dynamics in the pathogenesis of hypothalamic obesity in children. Eur J Pediatr. 2009; 168(9):1043–8.
40.
Siviero-MiachonAA, Spinola-CastroAM, Tosta-HernandezPD, et al.Leptin assessment in acute lymphocytic leukemia survivors: role of cranial radiotherapy?. J Pediatr Hematol Oncol. 2007; 29(11):776–82.
41.
GiovanniniL, TirabassiG, MuscogiuriG, et al.Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. Endocr J. 2015; 62(12):1037–48.
42.
FollinC, ThilenU, OsterbergK, et al.Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2010; 95(8):3726–35.
43.
BergWT, MinerM. Hypogonadism and metabolic syndrome: review and update. Curr Opin Endocrinol Diabetes Obes. 2020; 27(6):404–10.
44.
MarriottCJC, BeaumontLF, FarncombeTH, et al.Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: a focus on sarcopenic obesity. Cancer. 2018; 124(6):1225–31.
45.
DespresJP.Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012; 126(10):1301–13.
46.
SmithWA, LiC, NottageKA, et al.Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer. 2014; 120(17):2742–50.
47.
SchmitzKH, HoltzmanJ, CourneyaKS, et al.Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005; 14(7):1588–95.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
